Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614191 | 1.00 | CCR2 (0.31) | CCR2 | |
| SCHEMBL1657412 | 1.00 | CCR2 (0.31) | CCR2 | |
| SCHEMBL20660322 | 0.90 | CCR2 (0.36) | CCR2 | |
| SCHEMBL5997867 | 0.81 | — | — | |
| SCHEMBL9519653 | 0.81 | CCR2 (0.31) | CCR2 | |
| SCHEMBL11090998 | 0.81 | CCR2 (0.31) | CCR2 | |
| SCHEMBL9789673 | 0.81 | CCR2 (0.31) | CCR2 | |
| SCHEMBL25280121 | 0.73 | BACE1 (0.37) | — | |
| SCHEMBL27152796 | 0.73 | BACE1 (0.37) | — | |
| SCHEMBL25543706 | 0.73 | CCR2 (0.34) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| WO-2024197289-A1 | NEGATIVE ALLOSTERIC MODULATORS OF GLUN2B RECEPTORS AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024059169-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4281458-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | Anrui Biomedical Technology (Guangzhou) Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-117043164-A | Imidazopyridazine or pyrazolopyrimidine compounds and compositions | 安锐生物医药科技(广州)有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022156657-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-07-28 | — | — | WO | disclosed |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1810969-A1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-0620225-B1 | Cephalosporin derivatives | BASILEA PHARMACEUTICA AG (CH) | 2002-11-13 | — | — | EP | disclosed |
| US-5523400-A | 3-(PYRROLIDIN-3-YLIDENE=CH-),7-((2-AMINOTHIAZOL-4-YL)HYDROX -IMINOACETYLAMINO-)-3-CEPHEM DERIVATIVES; BROAD SPECTRUM ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0381984-B1 | 3- or 4-substituted oxotremorine derivatives | AMERICAN CYANAMID CO (US) | 1995-04-19 | — | — | EP | disclosed |
| EP-0620225-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1994-10-19 | — | — | EP | disclosed |
| US-5089518-A | 3- or 4-substituted oxotremorine derivatives and a method of treating cholinergic dysfunction therewith | AMERICAN CYANAMID COMPANY (US) | 1992-02-18 | — | — | US | disclosed |
| US-4952600-A | TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMERICAN CYANAMID COMPANY (US) | 1990-08-28 | — | — | US | disclosed |
| EP-0381984-A1 | 3- or 4-substituted oxotremorine derivatives | AMERICAN CYANAMID COMPANY (US) | 1990-08-16 | — | — | EP | disclosed |
| US-4937235-A | Anticholinergic agents | AMERICAN CYANAMID COMPANY (US) | 1990-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | TYK2, PTK2B, JAK1 | CCR2 949/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | CCR2 783/4885 |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | GCK, GCKR, SLC5A1 | CCR2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.